X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2065) 2065
Book Chapter (26) 26
Magazine Article (14) 14
Publication (3) 3
Book / eBook (1) 1
Conference Proceeding (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pembrolizumab (2098) 2098
science & technology (1399) 1399
life sciences & biomedicine (1375) 1375
immunotherapy (898) 898
oncology (881) 881
humans (699) 699
nivolumab (657) 657
melanoma (544) 544
patients (519) 519
metastasis (489) 489
chemotherapy (448) 448
immune checkpoint (405) 405
cancer (404) 404
lung cancer (390) 390
tumors (363) 363
cancer therapies (358) 358
metastases (330) 330
ipilimumab (328) 328
apoptosis (323) 323
clinical trials (315) 315
male (293) 293
female (283) 283
pd-1 protein (272) 272
antibodies, monoclonal, humanized - therapeutic use (253) 253
middle aged (249) 249
pd-l1 protein (247) 247
aged (241) 241
pd-1 (235) 235
care and treatment (229) 229
immunology (216) 216
pd-l1 (194) 194
programmed cell death 1 receptor - antagonists & inhibitors (191) 191
cell death (188) 188
non-small cell lung carcinoma (181) 181
antibodies, monoclonal, humanized - adverse effects (177) 177
case report (175) 175
medical prognosis (169) 169
mutation (167) 167
biomarkers (165) 165
atezolizumab (163) 163
antineoplastic agents, immunological - therapeutic use (159) 159
lymphocytes (158) 158
lung neoplasms - drug therapy (150) 150
neoplasms. tumors. oncology. including cancer and carcinogens (149) 149
adult (148) 148
ligands (148) 148
antineoplastic agents - therapeutic use (146) 146
treatment outcome (143) 143
cytotoxicity (141) 141
drug therapy (141) 141
immunotherapy - methods (141) 141
survival (141) 141
immune checkpoint inhibitors (140) 140
melanoma - drug therapy (134) 134
lymphocytes t (133) 133
antibodies, monoclonal - therapeutic use (131) 131
carcinoma, non-small-cell lung - drug therapy (131) 131
pharmacology & pharmacy (129) 129
review (129) 129
monoclonal antibodies (127) 127
fda approval (123) 123
toxicity (123) 123
aged, 80 and over (120) 120
antibodies (120) 120
research (117) 117
lung cancer, non-small cell (116) 116
immune system (113) 113
medicine & public health (113) 113
medical research (111) 111
analysis (109) 109
general & internal medicine (109) 109
antigens (108) 108
medicine, general & internal (107) 107
programmed cell death 1 receptor - immunology (107) 107
checkpoint inhibitors (104) 104
response rates (104) 104
small cell lung carcinoma (103) 103
antineoplastic agents, immunological - adverse effects (101) 101
non-small cell lung cancer (99) 99
antibodies, monoclonal, humanized - administration & dosage (97) 97
health aspects (95) 95
b7-h1 antigen - antagonists & inhibitors (94) 94
dermatology (93) 93
lymphomas (92) 92
antineoplastic combined chemotherapy protocols - therapeutic use (90) 90
hematology (90) 90
abridged index medicus (89) 89
immune checkpoint inhibitor (88) 88
inhibitors (88) 88
prognosis (88) 88
medicine, research & experimental (87) 87
research & experimental medicine (87) 87
studies (86) 86
immunoglobulins (85) 85
radiation therapy (78) 78
antineoplastic agents - adverse effects (76) 76
immune response (76) 76
melanoma - pathology (76) 76
medicine (75) 75
skin neoplasms - drug therapy (74) 74
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2052) 2052
German (17) 17
Russian (16) 16
French (12) 12
Chinese (11) 11
Korean (11) 11
Japanese (6) 6
Czech (3) 3
Italian (2) 2
Spanish (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of neurology, ISSN 0340-5354, 01/2020, Volume 267, Issue 1, pp. 282 - 284
Journal Article
Urologe. Ausgabe A, ISSN 0340-2592, 01/2019, Volume 58, Issue 1, pp. 45 - 48
Journal Article
The lancet oncology, ISSN 1470-2045, 09/2019, Volume 20, Issue 9, pp. 1239 - 1251
SummaryBackgroundPembrolizumab improved progression-free survival and overall survival versus ipilimumab in patients with advanced melanoma and is now a... 
Hematology, Oncology, and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Ipilimumab | Analysis | Index Medicus
Journal Article
Journal of thoracic oncology, ISSN 1556-0864, 09/2018, Volume 13, Issue 9, pp. 1393 - 1399
The aim of this study was to assess the efficacy of maintenance pembrolizumab in patients with extensive-stage SCLC after treatment with platinum and... 
SCLC | Pembrolizumab | Metastatic | Maintenance | Respiratory System | Oncology | Life Sciences & Biomedicine | Science & Technology | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2018, Volume 378, Issue 22, pp. 2078 - 2092
The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Carcinoma, Non-Small-Cell Lung - secondary | Aged, 80 and over | Adult | Female | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Treatment outcome | Care and treatment | Chemotherapy | Usage | Analysis | Lung cancer, Non-small cell | Drug therapy | Cancer | Epidermal growth factor receptors | Laboratories | Lung cancer | Non-small cell lung carcinoma | Cytotoxicity | Metastasis | Patients | Cancer therapies | Metastases | Pembrolizumab | Hospitals | Platinum | PD-L1 protein | Response rates | Death | Mutation | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2016, Volume 375, Issue 19, pp. 1823 - 1833
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2016, Volume 374, Issue 26, pp. 2542 - 2552
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2018, Volume 379, Issue 21, pp. 2040 - 2051
The addition of pembrolizumab, an anti–PD-1 antibody, to a platinum–taxane chemotherapy combination significantly prolonged progression-free and overall... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Lung Neoplasms - drug therapy | Double-Blind Method | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - mortality | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Non-Small-Cell Lung - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Intention to Treat Analysis | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Paclitaxel - administration & dosage | Chemotherapy | Usage | Safety and security measures | Lung cancer, Non-small cell | Drug therapy | Cancer | Statistical analysis | Tumor cells | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Metastasis | Patients | Cancer therapies | Evidence-based medicine | Metastases | Nanoparticles | Histamine | Pembrolizumab | Platinum | PD-L1 protein | Paclitaxel | Carboplatin | Death | Apoptosis | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article